Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma
- PMID: 15086556
- DOI: 10.1111/j.0022-202X.2004.22342.x
Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma
Abstract
There is increasing promise that cellular immune response may be manipulated to combat cancer; however, it is also clear that the immune response to cutaneous malignancy comprises different T cell activities that variably inhibit or promote tumor development. Thus, a better understanding of each of these activities is crucial to more effective clinical manipulation. To better characterize the protective anti-tumor effects of alphabeta T cells, we examined the growth of the transplantable squamous cell carcinoma (SCC) line, PDV, which is markedly inhibited in immunocompetent versusalphabeta T cell-deficient mice. We show that the protective response is composed of CD8(+) and interferon-gamma (IFNgamma)-producing CD4(+) cells, and that the most overt effects of these components on tumor growth in situ are to provoke overt focal necroses and to decrease the stromal bed. Tumors growing in the presence of any of these components also show reduced expression of Rae-1, a ligand for the activating NK receptor, NKG2D. Collectively, these data illustrate which components of the alphabeta T cell response against SCC have protective potential, and indicate which aspects of tumor physiology may be most susceptible to their activities.
Similar articles
-
Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis.Nat Immunol. 2008 Feb;9(2):146-54. doi: 10.1038/ni1556. Epub 2008 Jan 6. Nat Immunol. 2008. PMID: 18176566
-
Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer.Cancer Res. 2007 Dec 1;67(23):11195-201. doi: 10.1158/0008-5472.CAN-07-2637. Cancer Res. 2007. PMID: 18056444
-
The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.Int J Cancer. 2007 Sep 15;121(6):1282-95. doi: 10.1002/ijc.22795. Int J Cancer. 2007. PMID: 17520674
-
Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?Int Immunopharmacol. 2005 Jul;5(7-8):1099-111. doi: 10.1016/j.intimp.2005.03.003. Epub 2005 Apr 1. Int Immunopharmacol. 2005. PMID: 15914316 Review.
-
UL16 binding proteins.Immunobiology. 2004;209(3):283-90. doi: 10.1016/j.imbio.2004.04.008. Immunobiology. 2004. PMID: 15518340 Review.
Cited by
-
Investigating Cutaneous Squamous Cell Carcinoma in vitro and in vivo: Novel 3D Tools and Animal Models.Front Med (Lausanne). 2022 May 9;9:875517. doi: 10.3389/fmed.2022.875517. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35646967 Free PMC article. Review.
-
Topical arginase inhibition decreases growth of cutaneous squamous cell carcinoma.Sci Rep. 2021 May 24;11(1):10731. doi: 10.1038/s41598-021-90200-y. Sci Rep. 2021. PMID: 34031449 Free PMC article.
-
The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities.Front Cell Dev Biol. 2021 Feb 9;9:636544. doi: 10.3389/fcell.2021.636544. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33634137 Free PMC article. Review.
-
The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism.Molecules. 2019 Jun 11;24(11):2192. doi: 10.3390/molecules24112192. Molecules. 2019. PMID: 31212694 Free PMC article.
-
The Role of the Immune System in Cutaneous Squamous Cell Carcinoma.Int J Mol Sci. 2019 Apr 24;20(8):2009. doi: 10.3390/ijms20082009. Int J Mol Sci. 2019. PMID: 31022866 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials